Spero Therapeutics Past Earnings Performance
Past criteria checks 3/6
Spero Therapeutics has been growing earnings at an average annual rate of 34.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 52.1% per year. Spero Therapeutics's return on equity is 5.4%, and it has net margins of 3.3%.
Key information
34.1%
Earnings growth rate
43.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 52.1% |
| Return on equity | 5.4% |
| Net Margin | 3.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Spero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 106 | 4 | 23 | 33 |
| 30 Jun 24 | 118 | 17 | 24 | 0 |
| 31 Mar 24 | 111 | 23 | 24 | 0 |
| 31 Dec 23 | 104 | 23 | 26 | 0 |
| 30 Sep 23 | 78 | -2 | 26 | 33 |
| 30 Jun 23 | 54 | -10 | 27 | 0 |
| 31 Mar 23 | 54 | -27 | 28 | 0 |
| 31 Dec 22 | 54 | -46 | 36 | 0 |
| 30 Sep 22 | 9 | -102 | 43 | 0 |
| 30 Jun 22 | 10 | -113 | 48 | 0 |
| 31 Mar 22 | 13 | -103 | 49 | 0 |
| 31 Dec 21 | 18 | -90 | 42 | 0 |
| 30 Sep 21 | 17 | -79 | 36 | 0 |
| 30 Jun 21 | 18 | -76 | 30 | 0 |
| 31 Mar 21 | 15 | -74 | 26 | 0 |
| 31 Dec 20 | 9 | -79 | 21 | 0 |
| 30 Sep 20 | 11 | -85 | 18 | 0 |
| 30 Jun 20 | 12 | -84 | 17 | 0 |
| 31 Mar 20 | 12 | -80 | 16 | 0 |
| 31 Dec 19 | 18 | -61 | 16 | 0 |
| 30 Sep 19 | 16 | -47 | 15 | 0 |
| 30 Jun 19 | 12 | -39 | 14 | 0 |
| 31 Mar 19 | 11 | -36 | 14 | 0 |
| 31 Dec 18 | 4 | -42 | 13 | 0 |
| 30 Sep 18 | 3 | -46 | 12 | 0 |
| 30 Jun 18 | 3 | -47 | 12 | 0 |
| 31 Mar 18 | 3 | -50 | 12 | 0 |
| 31 Dec 17 | 2 | -46 | 11 | 0 |
| 30 Sep 17 | 1 | -40 | 11 | 0 |
| 30 Jun 17 | 1 | -35 | 9 | 0 |
| 31 Mar 17 | 0 | -30 | 7 | 0 |
| 31 Dec 16 | 0 | -30 | 7 | 0 |
Quality Earnings: 2HA has high quality earnings.
Growing Profit Margin: 2HA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2HA has become profitable over the past 5 years, growing earnings by 34.1% per year.
Accelerating Growth: 2HA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2HA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2HA's Return on Equity (5.4%) is considered low.